+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06275919

Multicenter Study Evaluating Regorafenib Versus Standard Care for Recurrent Meningioma

Led by Istituto Oncologico Veneto IRCCS · Updated on 2026-09-30

104

Participants Needed

20

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether Regorafenib can show antitumor activity against recurrent meningiomas, a type of malignant brain tumor. Previous small studies suggest that VEGF inhibitors may help control tumor growth, and Regorafenib targets several receptors and signaling pathways involved in meningioma development. It has shown promising activity in laboratory and animal studies and has been effective in other cancers, maintaining quality of life. Participants will be randomly assigned to receive either Regorafenib tablets orally at 160 mg daily for 3 weeks followed by 1 week off, continuing until disease progression or unacceptable side effects, or to receive the local standard of care treatment as determined by their site. This is a multicenter, Phase II study comparing these two approaches in patients with recurrent meningioma. During the study, participants will have regular assessments including MRI scans to monitor tumor progression, laboratory tests to check organ function, and evaluations of symptoms and quality of life. Researchers will measure progression-free survival over up to 54 months as the primary outcome, along with overall survival, response rate, patient-reported outcomes, toxicity, and disease control rate up to 42 months. The study will continue until March 2029.

CONDITIONS

Brief Title

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Research Team

G

Gian Luca De Salvo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here